Source comparison
MK-677 30s Age-Specific Protocol: Dosing Comparison by Health Status
Metabolically healthy, trains 4+ days/week, fasting glucose <90 mg/dL 20–25mg nightly 8 weeks on, 4 weeks off Fasting glucose at weeks 4 and 8 40–60% above baseline Optimal response window. Higher-end dosing justified by training stimulus and insulin sensitivi
This comparison does not assign a generated winner or score.
- Metabolically healthy, trains 4+ days/week, fasting glucose <90 mg/dL
- 20–25mg nightly
- 8 weeks on, 4 weeks off
- Fasting glucose at weeks 4 and 8
- 40–60% above baseline
- Optimal response window. Higher-end dosing justified by training stimulus and insulin sensitivity
- Metabolically healthy, trains 2–3 days/week, fasting glucose 90–95 mg/dL
- 15–20mg nightly
- Fasting glucose at weeks 2, 4, and 8
- 30–50% above baseline
- Standard protocol. Moderate dose balances anabolic benefit with metabolic safety
- Baseline fasting glucose 96–100 mg/dL or HbA1c 5.5–5.7%
- 15mg nightly + berberine 500mg BID
- 6 weeks on, 4 weeks off
- Fasting glucose weekly; consider CGM
- 25–40% above baseline
- Lower dose with insulin sensitizer co-administration. Shortened cycle reduces glucose exposure risk
- Pre-diabetic (fasting glucose >100 mg/dL, HbA1c >5.7%)
- Not recommended without physician oversight
- N/A
- MK-677 contraindicated. Growth hormone's anti-insulin effects compound existing dysregulation
- Post-injury recovery focus, normal metabolic health
- 20mg nightly
- Fasting glucose at weeks 4 and 8; track subjective recovery markers
- 35–55% above baseline
- Recovery-focused protocols benefit from mid-range dosing. Anabolic window aligns with tissue repair phase
- Late 30s (37–39) with declining baseline IGF-1 (<180 ng/mL)
- IGF-1 at week 2 and week 6; fasting glucose at weeks 4 and 8
- Age-related decline justifies higher-end dosing if metabolic health permits. Monitor IGF-1 response to confirm adequate receptor sensitivity